Immune reconstitution after bone marrow transplantation (BMT) recapitulates immune ontogeny. At birth there is an imbalance in lymphokine production, with decreased production of interferon-y (IFN-y) compared with interleukin4 (IL-4) and IL-2. We investigated whether a similar imbalance in lymphokine production occurs in BMT recipients within 6 months after transplantation. Our results show that BMT recipients not treated with immunosuppressive drugs have a decrease in IFN-7 production and IL-2, in comparison with IL-4. This imbalance was likely to result from impaired signal transduction through surface receptors, because it was detectable on stimulation with Concanavalin A (ConA), but was XPRESSION OF lymphokines during the maturation E of the immune system is known to occur sequentially.
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Interleukin-4 (IL-4) production has been detected in fetal thymocytes,',' while the production of interferon-y (IFN-y) is selectively delayed. Neonatal lymphocytes produce only 10% as much IFN-y as adult cells, after stimulation with Concanavalin A (ConA) or phytohemagglutinin (PHA). In contrast, IL-2 expression is comparable in neonates and ad~lts.3,~ Thus, at birth there is an imbalance in lymphokine production, which is characterized by a relative increase in the production of IL-4 and IL-2 in comparison with IFN-y. The decreased production of IFN-y may contribute to the increased susceptibility to infections observed in human neonates?
Immune reconstitution after bone marrow transplantation (BMT) recapitulates immune ontogeny: Early after BMT, both T-and B-cell function are depressed and this abnormality may account for the enhanced susceptibility to infections. Concomitantly, abnormal activation of immune cells is detectable, with increase in spontaneous IgM and The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S. IgG production, increase in serum IgE levels and in spontaneous IgE synthesis in vitro, and eosinophilia with a decrease in the density of eosinophil^."^ These findings are often accompanied by the manifestations of graft-versushost disease (GVHD) (fever, skin rash, impairment of liver function, gastrointestinal disturban~es).~"~ We explored the possibility that an imbalance in lymphokine production similar to the one observed in early immune ontogeny might occur in BMT recipients early after transplantation. To test this hypothesis, we assessed the ability of peripheral blood mononuclear cells (PBMC) from 27 BMT recipients ( I 6 months postgrafting) to produce IL-4, IFN-y, and IL-2 after activation by different stimuli. As mitogens, we chose ConA, which delivers an activating signal via surface receptors," and phorbol myristate acetate (PMA) + ionophore, which bypass surface receptors and mimick the effects of second messengers." We observed that BMT recipients not treated with immunosuppressive drugs produce less IFN-y and IL-2 relative to IL-4. This imbalance is likely to result from impaired signal transduction through surface receptors. Patients treated with immunosuppressive drugs (cyclosporine A [CsA], corticosteroids) show an additional deficit, which affects signaling downstream of second messenger generation.
MATERIALS AND METHODS
Patients. Twenty-seven BMT recipients were studied within 6 months from transplantation (Table 1) . Twenty-six patients received allogeneic BMT from HLA-A, -B, -C, and -D histocompatible siblings; one patient had a donor who was a one-loci mismatch. Patients receiving transplants for leukemic disorders were conditioned with cytosine arabinoside, cyclophosphamide, and total body irradiation (TBI),I3 or with busulfan and cyclophosphamide.I4 GVHD prophylaxis regimens included four doses of methotrexate with CsA (administered for 6 months unless toxicity occurred as with patients 8 and lo), or ex vivo donor marrow T-cell depletion using anti-CDS monoclonal antibody (MoAb) + immunotoxin." 
Abbreviations: MTX, methotrexate; S, steroids. *Patient studied before treatment for acute GVHD. tPatient studied after brief treatment for acute GVHD with steroids (SB) or after GVHD prophylaxis with CsA (SL, KM, JB). *Chronic GVHD.
macia Fine Chemicals, Piscataway, NJ), washed three times in Hanks' balanced salt solution (Microbiological Associates, Bethesda, MD), and resuspended at l x lo6 (for IFN-y and IL-2 assays) or 3 x lo6 (for IL-4 assays) cells/mL in RPMI 1640-10% AB+ serum (Flow Labs, Inc, McLean, VA) supplemented with 2 mmol/L L-glutamine, 50 pg/mL streptomycin, and 100 U/mL penicillin (complete medium).
PBMC were cultured at 37°C in media alone, with ConA (Calbiochem, La Jolla, CA; 10 pg/mL) or PMA (Sigma Chemical Co, St Louis, MO; 50 ng/mL) + ionomycin (Calbiochem; 1.0 kmol/L). After 24 hours (for IL-4 assays) and 48 hours (for IFN-y and IL-2 assays), supernatants were harvested and stored at -20°C.
IL-4 concentrations were determined by a specific immunoenzymetric assay16 (lower limit of sensitivity: 75 pg/mL). IFN-y concentrations were determined using a specific, commercially available radioimmunoassay (RIA; Centocor, Malvern, PA) (lower limit of sensitivity: 2 U/mL). IL-2 concentrations in the supernatants were determined using a commercially available RIA (Amersham International, Amersham, UK) (lower limit of sensitivity: 14 fmol/mL).
PBMC (1 x lo5 cells in 0.1 mL of complete medium) were cultured in 96-well plates with mitogens, as indiLymphokine assays.
Proliferation assays. Statistical analysis. This was performed by using the Student's t-test for unpaired samples. 
RESULTS

treated.
the patients was 30 2 2 years and 30 f 6 years for the control group. Eleven patients were receiving no immunosuppressive drugs at the time of the study; 16 patients were treated with CsA and/or corticosteroids. Because these agents are known to be potent immunosuppressants, untreated and treated patients were analyzed separately. The treated and untreated groups were similar in their ages and time after transplant. Eight patients in the untreated group had grade zero acute GVHD, three patients had grade 1 acute GVHD, and none had grade 2 or greater GVHD. Five of 16 in the treated group had grade 0 acute GVHD, six had grade 1 GVHD, and five had grade 2. Patients in the treated group were receiving immunosuppressives either for GVHD prophylaxis (n = 7). acute GVHD (n = 4), or both (n = 5).
Percentages of circulating CD3' cells (CD3%), lymphoproliferative responses, and lymphokine production were assessed at the same time in each patient included in our study. CD3% in both untreated and treated BMT recipients was significantly ( P = .001) decreased as compared with controls (43 2 5 and 49 f 5, respectively, v 75 2 9).
Proliferative responses of PBMC from BMT recipients. Figure 1 shows that proliferation to ConA was significantly decreased in PBMC from both untreated ( P = .002) and treated (P < .001) BMT recipients, as compared with normal controls. Proliferation to PMA + ionomycin was
within the normal range in untreated patients. This finding suggests that impaired signal transduction through the CD3/T cell receptor complex may underlie the decreased proliferation to ConA in untreated BMT recipients. In contrast, proliferation to PMA + ionomycin in treated patients was significantly ( P < .001) impaired as compared with controls. This result suggests that the T-cell activation defect in treated BMT recipients involves events downstream of second messenger generation.
Lymphokine production by PBMC from BMT recipients. Figure 2 shows that IFN-y production after ConA stimulation was significantly decreased in both untreated ( P = .02) and treated ( P = .002) BMT recipients. In contrast, IFN-y production after stimulation with PMA + ionomycin was within the normal range in untreated patients, but remained significantly ( P = .003) diminished in treated patients. IFN-y production by unstimulated cells was below the sensitivity of the assay (2 U/mL). Figure 3 shows that ConA-induced IL-2 production was significantly decreased in the two BMT recipients' groups compared with controls ( P = .02, P = .002). Production of IL-2 after stimulation with PMA + ionomycin was significantly higher than that observed with ConA in both treated and untreated groups. However, it remained significantly decreased in both treated ( P = .001) and untreated ( P = .009) patients, compared with controls. IL-2 production by unstimulated cells was below the sensitivity of the assay (14 fmol/mL).
In agreement with a previous report," IL-4 secretion by unstimulated or ConA-stimulated PBMC from both patients and controls was below the limit of sensitivity of the assay (75 pg/mL). Figure 4 shows that IL-4 production after stimulation with PMA + ionomycin was within the normal range in both untreated and treated BMT recipients.
When the treated group was further subdivided and analyzed on the basis of GVHD (patients with grade 2 v paticnts with grade 0 and l), or on the basis of therapy with or without cyclosporine, there was no statistical difference in lymphokine production or proliferation between the subgroups.
DISCUSSION
Our results show that the pattern of lymphokine production in recipients of BMT within 6 months posttransplantation is closely similar to the one observed during immune ontogeny: in that production of IFN-y after stimulation -r T Untreated BMT recipients exhibited an impairment in signal transduction through the CD3/T cell receptor complex. Proliferation and IFN-y production were markedly decreased after stimulation with ConA, but were corrected by the addition of PMA + ionophore, which bypass surface receptor signaling." In accord with our data, the ability to flux calcium after CD3/TCR stimulation is defective early after BMT." Interestingly, the decrease in IFN-y and proliferation persisted even after the data was corrected for CD3%. Furthermore, CD3 density was not significantly affected in our patients (data not shown). Thus, the impairment in proliferation and lymphokine secretion points to a qualitative defect in signal transduction possibly resulting from immaturity of the immune system during recovery after transplantation.
The pattern observed for IL-2 production in untreated BMT recipients was only apparently different. Although IL-2 release after stimulation with PMA + ionophore was lower than that observed in normals, IL-2 secretion in PMA + ionophore-stimulated cultures was substantially increased (approximately 1 1-fold) in comparison with ConAtreated cultures and, most importantly, was sufficient to support normal proliferation. Thus, IL-2 production in untreated BMT patients was reconstituted in functional if not in quantitative terms by agents that bypass surface receptors signaling. IL-4 production in untreated BMT recipients was preserved, while secretion of the major.antagonist, IFN-y, was decreased. Because detectable IL-4 secretion could only be triggered by "nonphysiologic" stimuli, such as PMA and ionophore, this finding should be interpreted cautiously. However, an increase in IL-4, and possibly in the other Th2-like lymphokine, IL-5: '' relative to IFN-y would be consistent with several clinical features of BMT recipients, eg, enhanced IgE production? B-cell activation, eosinophilia,*' and the observed expansion of the CD4'/CD45R-T-cell subset (Schneider et al, unpublished data), the putative memory T-cell population to which IL-4 production may be restri~ted.".'~ On the other hand, the deficit in IFN-y may underlie the increased susceptibility to infections that typically occurs after BMT.
BMT recipients treated with immunosuppressants (CsA and/or corticosteroids) exhibited an additional signaling defect downstream of PKC activation, because proliferation, IFN-y, and IL-2 production were impaired after stimulation with PMA + ionophore, as well as ConA. The signaling defect could have resulted from GVHD and/or the immunosuppressive treatment. Decreased production of IFN-y and IL-2 has been observed during GVHD.22.23 On the other hand, CsA has been reported to strongly inhibit the expression of IL-2 and IFN-y genes both in vitro and after in vivo admini~tration:~ while IL-2 receptor expression and IL-2 responsiveness are preserved.ZS.26 Corticosteroids are in turn known to have contrasting effects on the production of IL-2 and IL-4 both in vivo and in vitro. IL-2 production is profoundly suppressed,2'.*' while the synthesis of IL-4 is intact or even enhanced.*' The latter observation is consistent with our findings of normal IL-4 production in BMT patients treated with immunosuppressants.
The deficiency in cytokine production described in this report may explain some of the immunologic abnormalities observed in BMT recipients. Furthermore, it provides a model for the study of the signals that are essential for the optimal production of various lymphokines.
